CUTANEOUS SKELETAL HYPOPHOSPHATEMIA SYNDROME (CSHS)

Clinical trials for CUTANEOUS SKELETAL HYPOPHOSPHATEMIA SYNDROME (CSHS) explained in plain language.

Never miss a new study

Get alerted when new CUTANEOUS SKELETAL HYPOPHOSPHATEMIA SYNDROME (CSHS) trials appear

Sign up with your email to follow new studies for CUTANEOUS SKELETAL HYPOPHOSPHATEMIA SYNDROME (CSHS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Can a drug for one bone disease help another? a Rare-Disorder trial puts it to the test

Disease control Completed

This early-phase trial is testing whether burosumab, a drug already approved for X-linked hypophosphatemia (XLH), can safely raise phosphate levels in a single patient with cutaneous skeletal hypophosphatemia syndrome (CSHS). Both conditions involve abnormally high FGF23 activity…

Matched conditions: CUTANEOUS SKELETAL HYPOPHOSPHATEMIA SYNDROME (CSHS)

Phase: EARLY_PHASE1 • Sponsor: Laura Tosi • Aim: Disease control

Last updated Aug 01, 2026 00:00 UTC

CUTANEOUS SKELETAL HYPOPHOSPHATEMIA SYNDROME (CSHS)

Get alerted when new CUTANEOUS SKELETAL HYPOPHOSPHATEMIA SYNDROME (CSHS) trials appear

Can a drug for one bone disease help another? a Rare-Disorder trial puts it to the test